Novel Inhibitors of 5α-Reductase

The document from February 2002 reviews the development of novel inhibitors of 5α-reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT) and is associated with conditions such as benign prostatic hyperplasia (BPH), male pattern baldness, and hirsutism. It discusses the significance of these inhibitors, particularly in treating androgenetic alopecia and BPH, and the challenges in discovering new inhibitors due to the lack of structural information on the enzyme. The document details steroidal inhibitors, including 4-azasteroids like finasteride, and nonsteroidal inhibitors, emphasizing the need for selectivity in inhibitor development. It also mentions various compounds with potent inhibitory effects, such as compound 33 with an IC50 value of 7.6 nM against 5αR-1, and highlights the importance of testing on human isoenzymes due to species specificity. The document concludes that further research is needed to design new inhibitors and that understanding the enzyme's active site structure would aid this effort.